+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 2
89 locations
P

Actively Recruiting

Researchers are studying PRL-02 depot, a potential injectable treatment for men with advanced prostate cancer, including those whose cancer has returned or not responded to previous treatments. The trial aims to evaluate the safety and tolerability of PRL-02 depot alone or combined with enzalutamide, as well as to determine the appropriate dose. This Phase 1 study is sponsored by Astellas Pharma Global Development, Inc. and focuses on men with metastatic or biochemical relapse forms of prostate cancer. Participants will be divided into groups receiving different doses of PRL-02 depot injected into a muscle every 12 weeks. They will also take daily oral doses of either dexamethasone, prednisone, or enzalutamide depending on their study group and prior treatments. The study has two parts dose escalation with small groups receiving increasing doses, and dose expansion involving men previously treated with specific hormone therapies. During the trial, men will visit the clinic multiple times for health checks, scans, and blood tests to monitor side effects, disease progression, and testosterone suppression. After the final visit, those whose cancer has not worsened will continue to have periodic health assessments and scans. The main outcomes include tracking dose limiting toxicities and adverse events over up to four years, along with detailed pharmacokinetic and response measurements.

Age: 18Years +MALEPhase 1
25 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
S

Actively Recruiting

Researchers are evaluating whether combining pasritamig with docetaxel can extend the time before disease progression, measured by scans or death, compared to docetaxel alone in adults with metastatic castration-resistant prostate cancer. This type of prostate cancer continues to grow despite low male hormone levels. The study is a Phase 3 randomized trial designed to compare these treatments in this patient population. Participants are assigned to one of two groups. One group receives pasritamig together with docetaxel until disease progression or treatment end. The other group receives docetaxel plus prednisone or prednisolone as background medication. The study uses imaging scans and other criteria to monitor disease progression. The study treatment continues until certain protocol-defined endpoints are met. During the study, participants undergo various scans including CT, MRI, and bone scans to assess disease status. Researchers monitor progression-free survival and other outcomes such as overall survival, symptom progression, and quality of life using questionnaires. Safety is tracked by recording adverse events, lab abnormalities, and treatment side effects. Follow-up lasts up to about four and a half years, allowing comprehensive evaluation of treatment impact and safety.

Age: 18Years +All GendersPhase 3
165 locations
P

Actively Recruiting

Researchers are evaluating the overall survival of pasritamig JNJ-78278343, alone or combined with JNJ-87189401, compared to placebo in men with metastatic castration-resistant prostate cancer mCRPC, a cancer that has spread beyond the prostate and no longer responds to hormone therapies. This Phase 3 trial aims to assess these treatments alongside best supportive care BSC to improve outcomes in late-line mCRPC. Participants receive study treatments through intravenous infusions, including two step-up doses of pasritamig or placebo followed by the target dose. In Part 2, some participants also receive JNJ-87189401 with pasritamig. Treatments continue until disease progression, intolerable side effects, death, withdrawal, or study end. All participants may receive BSC, which includes palliative radiation, steroids, pain medications, bone agents, and related procedures as needed. During the study, participants are monitored for survival, disease progression, symptoms, pain, fatigue, and side effects for up to 2 years and 8 months. Assessments include clinical labs and quality-of-life questionnaires. Researchers track adverse events and laboratory abnormalities to evaluate safety. The study supports ongoing care while measuring the impact of these treatments in advanced prostate cancer.

Age: 18Years +MALEPhase 3
176 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the XEN63 glaucoma gel stent implanted using two different surgical methods ab interno inside the eye and ab externo outside the eye. This study focuses on patients with glaucoma who have not responded well to medical treatments or conventional surgeries. The trial aims to compare outcomes such as adverse events and intraocular pressure control over 12 months. Participants will be randomly assigned to receive the XEN63 gel stent implanted via either the ab interno or ab externo approach on Day 1. About 130 adults aged 45 years or older with glaucoma will join this study. After implantation, participants will be followed for up to 12 months with regular hospital or clinic visits to monitor safety and effectiveness. During the study, participants will undergo medical assessments and eye exams to measure intraocular pressure and check for any adverse events. The main outcomes include the percentage of participants achieving a 20% or greater reduction in intraocular pressure on the same or fewer medications after 12 months. Secondary measures include changes in daily intraocular pressure and medication use. The study will be completed by November 2028.

Age: 45Years +All GendersPhase 3
29 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
E

Actively Recruiting

Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.

Age: 18Years +All GendersPhase 3
193 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NEXAGON4 lufepirsen ophthalmic gel in people with persistent corneal epithelial defects PCED, a condition where the corneal surface does not heal properly. This randomized, double-masked, vehicle-controlled study aims to understand how well NEXAGON works in treating PCED and its durability after treatment. This Phase 2 trial is sponsored by Glaukos Corporation and is conducted at multiple centers. Participants will be randomly assigned to receive one of three treatments applied topically to the eye once a week for 4 to 8 weeks a high dose of lufepirsen, a low dose of lufepirsen available only at EU sites, or a vehicle gel without the active drug. After the treatment period, a 4-week follow-up will monitor the condition. If the corneal defect does not heal or the healing is not maintained for 28 days, participants may enter an open-label treatment phase with NEXAGON for an additional 8 weeks. During the study, participants will undergo screening to confirm eligibility, receive weekly treatment applications, and be monitored for safety and healing progress. Researchers will assess corneal re-epithelialization and its durability as the main outcome. The total study participation includes the screening, up to 8 weeks of treatment, 4 weeks of follow-up, and possibly an 8-week open-label extension. Safety, efficacy, and healing durability will be closely observed throughout these periods.

Age: 2Years +All GendersPhase 2
28 locations
E

Actively Recruiting

Researchers are studying a treatment for adults with muscle-invasive bladder cancer, a condition where cancer has spread into the muscle wall of the bladder. The usual approach involves chemotherapy followed by bladder removal surgery, which can cause significant long-term changes. This study focuses on using a combination of enfortumab vedotin and pembrolizumab to help people keep their bladder, especially for those who respond well to this therapy and wish to avoid surgery. Participants will receive infusions of enfortumab vedotin on the 1st and 8th days of every 3-week cycle, along with pembrolizumab on the 1st day of each cycle. Treatment continues unless the cancer worsens, does not improve after 9 cycles, or if other medical reasons arise. Those whose cancer does not respond may need surgery, radiotherapy, or chemotherapy. The study monitors safety and tumor status regularly during these cycles. Throughout the study, participants will have safety checks at each visit, tumor assessments at some visits, and medical monitoring. After stopping treatment, health checks and scans occur every 3 months for 2 years, then every 6 months for up to 5 years if the cancer remains stable. Once cancer progresses, scans stop, but telephone health checks continue every 3 months. The main outcomes measured are the rate of complete response to treatment and the duration participants keep their bladder intact over two years.

Age: 18Years +All GendersPhase 2
68 locations

1-10 of 25

1